(P128) Bi-Institutional Cosmetic Outcome of Radiotherapy for Benign Lymphoepithelial Cysts of Parotid Glands in HIV Patients

OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

The long-term outcomes of radiation therapy (RT) in patients infected with human immunodeficiency virus (HIV) who have benign lymphoepithelial cysts (BLECs) of the parotid glands are reported.

Waleed F. Mourad, MD, MSc, PhD, Chengtao Wang, MD, PhD, John J. Lukens, MD, Shyamal Patel, MD, Rafi Kabarriti, MD, Rebekah Young, MD, Catherine Concert, DNP, Magdalena Ryniak, MA, RN, Rania A. Shourbaji, MPH, Daniel Shasha, MD, Madhur K. Garg, MD, Kenneth S. Hu, MD, Shalom Kalnicki, MD, Louis B. Harrison, MD; Beth Israel and Montefiore Medical Centers; Albert Einstein College of Medicine

Aim: To report the long-term outcomes of radiation therapy (RT) in patients infected with human immunodeficiency virus (HIV) who have benign lymphoepithelial cysts (BLECs) of the parotid glands.

Methods: This is a bi-institutional retrospective study of HIV-associated BLECs of the parotids. The medical records of 67 HIV-positive patients treated with RT between 1987 and 2012 were reviewed. Patients were stratified into two groups: Group A consisted of 15 patients (22%) who received a total dose of ≤ 18 Gy with a median dose 10 Gy (range: 8–18 Gy), and Group B consisted of 52 patients (78%) who received a total dose of 24 Gy. Bilateral parotids were treated with RT. The median age at RT, HIV diagnosis, and duration of HIV seropositivity was 42 years (range: 7–70 yr), 38 years (range: 23–53 yr), and 11 years (range: 6–35 yr), respectively.

Results: After a median follow-up of 38 months (range: 12–141 mo) for the entire cohort, the overall response (OvR) was 66%. Specifically, complete response (CR) and partial response (PR) were 55% and 11%, respectively. Fourteen of 15 patients (93%) in Group A (≤ 18 Gy) eventually experienced local failure (LF) with the re-emergence of parotid hypertrophy. Among the patients in Group B (24 Gy), 69%, 14%, and 17% experienced CR, PR, and LF, respectively. Median times to failure in Groups A and B were 7 and 20 months, respectively (P < .0001). Similarly, logistic regression analysis revealed the higher dose to be associated with better response rate (ie, CR or PR) (P < .0001), which was also statistically significant (P = .03) after adjusting for confounding variables (age, race, gender, highly active antiretroviral therapy [HAART] use, and fractionation). No patients in either group experienced Radiation Therapy Oncology Group (RTOG) toxicities ≥ grade 2. Specifically, patients experienced mucositis (48%), xerostomia (45%), skin erythema (41%), and altered taste (14%).

Conclusion: Our data show that 24 Gy is a well-tolerated radiation dose for sustainable cosmetic control of BLECs of the parotid glands in HIV patients.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content